|
|||||
|
|
| miR-155在弥漫性大B细胞淋巴瘤预后预测中的应用价值 | |
| 引用本文： | 李 星1,石 昊2. miR-155在弥漫性大B细胞淋巴瘤预后预测中的应用价值[J]. 现代肿瘤医学, 2021, 0(2): 307-311. DOI: 10.3969/j.issn.1672-4992.2021.02.027 |
| 作者姓名： | 李 星1 石 昊2 |
| 作者单位： | 1.延安市人民医院肿瘤血液科；2.耳鼻咽喉头颈外科,陕西 延安 716000 |
| 摘 要： | 目的:探讨miR-155在弥漫性大B细胞淋巴瘤预后预测中的应用价值。方法:选取我院收治的120例弥漫性大B细胞淋巴瘤作为研究对象，采用qRT-PCR检测所有患者癌组织miR-155的相对表达水平，根据miR-155的表达水平将所有患者分成miR-155高表达组（n=72）和miR-155低表达组（n=48），比较两组患者的临床病理资料、生存率，采用 Cox比例风险回归模型对弥漫性大B细胞淋巴瘤患者的预后进行单因素和多因素分析，并分析miR-155对弥漫性大B细胞淋巴瘤细胞增殖和迁移能力的影响。结果:miR-155高表达组患者结外侵犯比例显著高于miR-155低表达组（P＜0.05）；miR-155高表达组患者3年无进展生存率（29.2%）及总体生存率（40.3%）均显著低于miR-155低表达组（81.3%和83.3%）；单因素和多因素分析结果均显示miR-155表达水平是DLBCL无进展生存期和总体生存期的影响因素；miR-155低表达组细胞划痕愈合速度(0.53±0.04)显著低于对照组细胞（1.0±0.03）(P＜0.05)，miR-155低表达组细胞在培养的3、4 d的吸光度值显著低于对照组（0.38±0.01 vs 0.56±0.03；0.56±0.02 vs 0.76±0.02）（P＜0.05）。结论:弥漫性大B细胞淋巴瘤患者的miR-155表达水平显著影响患者的预后，其可能机制是通过影响弥漫性大B细胞淋巴瘤细胞的增殖和迁移能力，提示miR-155可能是弥漫性大B细胞淋巴瘤新的和可靠的预后生物标志物，值得进一步深入研究。 |
| 关 键 词： | miR-155 弥漫性大B细胞淋巴瘤 预后 |
miR-155 in predicting prognosis of diffuse large B-cell lymphoma |
|
| LI Xing1,SHI Hao2. miR-155 in predicting prognosis of diffuse large B-cell lymphoma[J]. Journal of Modern Oncology, 2021, 0(2): 307-311. DOI: 10.3969/j.issn.1672-4992.2021.02.027 | |
| Authors: | LI Xing1 SHI Hao2 |
| Affiliation: | 1.Department of Oncology and Hematology;2.Department of Otolaryngology,Head and Neck Surgery,Yan’an People’s Hospital,Shaanxi Yan’an 716000,China. |
| Abstract: | Objective:To evaluate the value of miR-155 in predicting prognosis of diffuse large B-cell lymphoma.Methods:120 cases of diffuse large B-cell lymphoma in our hospital were selected as the subjects.The relative expression of miR-155 in all patients was detected by qRT-PCR.According to the expression level of miR-155,all patients were divided into two groups:high expression of miR-155 (n=72) and low expression of miR-155 (n=48).The clinicopathological data and survival rate of the two groups were compared.The Cox proportional hazard regression model was used to analyze diffuse large B patients.The prognosis of patients with cell lymphoma was analyzed by single factor and multi-factor,and the effect of miR-155 on the proliferation and migration of diffuse large B-cell lymphoma cells was analyzed.Results:The percentage of extranodal invasion in patients with high expression of miR-155 was significantly higher than that in patients with low expression of miR-155(P＜0.05),and the 3-year non-progression-free survival rate(29.2%) and the overall survival rate(40.3%) of the miR-155 high-expression group were significantly lower than that of the miR-155 lower-expression group(81.3% and 83.3%)(P＜0.05).The single-factor and multi-factor analysis results showed that the miR-155 expression level is the influencing factor of the progression-free survival and overall survival of the DLBCL.The healing rate of scratches in the low expression group of miR-155(0.53±0.04) was significantly lower than that in the control group(1.00±0.03)(P＜0.05).The absorbance of cells in the low expression group of miR-155 was significantly lower than that in the control group on the 3rd and 4th day after culture(0.38±0.01 vs 0.56±0.03,0.56±0.02 vs 0.76±0.02)(P＜0.05).Conclusion:The expression level of miR-155 in patients with diffuse large B-cell lymphoma significantly affects the prognosis of the patients,and the possible mechanism is that it can affect the prognosis of patients with diffuse large B-cell lymphoma.The ability of proliferation and migration of cell lymphoma suggests that miR-155 may be a new and reliable prognostic biomarker for diffuse large B-cell lymphoma,which deserves further study. |
| Keywords: | miR-155 diffuse large B-cell lymphoma prognosis |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 | |
| 点击此处可从《现代肿瘤医学》下载免费的PDF全文 | |